💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, reasonably priced.
NGL Fine Chem is scored on the pharma / healthcare framework. It keeps a slim 9.3% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.90×). Free cash flow is worth about -1.6% of its market value.
Over the last 3 years revenue compounded at 22%/yr and profit at 33%/yr. Book value has grown 14%/yr. Return on equity is a healthy 14.6%. In the latest quarter profit grew 36% versus the prior quarter.
At 36× earnings, the stock sits at the 39th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~15%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 30.35 | — | — |
| P/B | 5.27 | 4.11 | worse |
| EV/EBITDA | 18.71 | 19.15 | better |
| ROE | 14.62 | — | — |
| ROCE | 15.37 | 6.87 | better |
| ROA | 10.49 | — | — |
| Quick Ratio | 1.37 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 22% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (33% vs 22%) — margin expansion is at work. The latest year saw a +128% swing — check if it's a one-off or structural.
Operating margin has expanded from 10% to 12% — the business is keeping more of each rupee earned.
ROE at 15% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 5pp across the window.
33% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Investing outflows exceed operating cash — the company relies on external funding to finance expansion. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 17% above earlier ones.
Profit jumped 36% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (8% → 13%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 72.5% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.